J. Goldman & Co LP Acquires Shares of 270,100 Heron Therapeutics, Inc. (NASDAQ:HRTX)

J. Goldman & Co LP bought a new position in shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 270,100 shares of the biotechnology company’s stock, valued at approximately $413,000. J. Goldman & Co LP owned about 0.18% of Heron Therapeutics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Nicolet Advisory Services LLC acquired a new position in Heron Therapeutics during the fourth quarter worth $25,000. Argent Advisors Inc. acquired a new position in Heron Therapeutics in the 4th quarter valued at about $31,000. Focus Partners Wealth acquired a new position in Heron Therapeutics in the 4th quarter valued at about $31,000. Cutter & CO Brokerage Inc. increased its holdings in shares of Heron Therapeutics by 69.6% during the 4th quarter. Cutter & CO Brokerage Inc. now owns 33,135 shares of the biotechnology company’s stock worth $51,000 after buying an additional 13,600 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Heron Therapeutics by 23.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,179 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 8,684 shares during the period. 80.01% of the stock is currently owned by institutional investors and hedge funds.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $2.11 on Monday. The company’s 50 day simple moving average is $2.19 and its 200-day simple moving average is $1.82. The company has a market capitalization of $321.91 million, a price-to-earnings ratio of -11.72 and a beta of 1.33. Heron Therapeutics, Inc. has a 1 year low of $1.04 and a 1 year high of $3.93.

Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.01) by $0.02. The company had revenue of $38.90 million during the quarter, compared to analyst estimates of $37.08 million. Equities analysts expect that Heron Therapeutics, Inc. will post -0.13 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently weighed in on HRTX. StockNews.com lowered Heron Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 8th. Needham & Company LLC reaffirmed a “buy” rating and issued a $4.00 price target on shares of Heron Therapeutics in a research note on Friday, April 11th.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.